In support of this, treatment of BrM explants from human donor eyes with short heparan sulfate oligosaccharides or an ApoA-1 mimetic was sufficient to remove lipoproteins from BrM.23 In addition, aged nonhuman primates that got an intravitreal injection of an ApoA-1 mimetic had less neutral lipid, esterified cholesterol, and activated complement components in BrM than placebo-treated controls.241 Pharmaceutical interventions aimed at lipoprotein binding in BrM may be effective in the treatment of AMD and should be considered in future studies involving AMD mouse models. Here, APOA1 is linked to age-related macular degeneration.